Compare State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF (FLRN) vs TG Therapeutics Inc (TGTX) Price & Performance

FLRN trades at $30.77, showing minimal daily change of 0.03%. Technical indicators signal a bearish trend with moving averages and ADX pointing downward, though RSI suggests potential oversold conditions. The company has maintained consistent dividend payments of $0.11 per share through mid-2026. Key financial ratios including P/E, P/S, and ROE remain unavailable in current data.

Investment outlook remains cautious due to bearish technical signals and lack of current fundamental data. The consistent dividend provides income stability, but without updated financial metrics, assessing valuation and growth prospects is challenging. Primary risks include reliance on historical dividend patterns and potential market volatility amid inflationary pressures.

TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.

The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.